Uncategorized

Tirzepatide plateau at 3 months happens when adaptive thermogenesis kicks in. Here’s how metabolic adaptation works and what adjustments restart progress.

Semaglutide microdosing carries risks most guides ignore: receptor desensitisation, dose inconsistency, and loss of therapeutic efficacy. Here’s what

Semaglutide microdosing starts at 0.25–0.5mg weekly, titrating slowly to minimize side effects while achieving sustained weight loss through optimized

Semaglutide shows metabolic benefits that may slow aging markers — but it’s not a longevity drug. Here’s what the evidence actually supports.

Semaglutide reduces cardiovascular mortality by 20% and slows biological aging markers, but lifespan extension requires sustained metabolic correction

Semaglutide shows neuroprotective effects through GLP-1 receptor activation in the brain, reducing inflammation and potentially improving cognitive

Semaglutide doesn’t treat addiction, but may reduce cravings in recovery by modulating dopamine pathways. Here’s what the research shows and doesn’t.

Semaglutide shows emerging neuroprotective effects in Parkinson’s research. Early trials suggest GLP-1 receptor activity may slow motor symptom

Semaglutide shows 40-70% reduction in Alzheimer’s risk across multiple trials. Mechanisms, dosing, and what patients need to know about GLP-1